5 % of the initial etoposide concentration The decreased etoposi

5 % of the initial etoposide concentration. The decreased etoposide concentration in disposable infusion Saracatinib purchase devices was therefore only due to the formation of an etoposide precipitate. This decrease in concentration may PRN1371 be considered as entirely due to the phenomenon of precipitation, and not to the formation of degradation products. 4 Conclusion Regarding changes in the concentration of the active substance, we can conclude that (i) in low-dose solutions (100 mg/L), etoposide was stable up to 12 h in D5W and up to 24 h in NaCl 0.9 %, both at room temperature and at 33 °C; (ii) etoposide was stable up to 24 h in 400-mg/L solutions, in NaCl 0.9 % and D5W, both at room temperature and at 33 °C;

and (iii) etoposide was stable in 600-mg/L solutions for 8 h at room temperature and for 6 h at 33 °C, in

NaCl 0.9 % and D5W. After 24 h, quantification of Stattic cost the precipitate and of etoposide in solution showed that 100 % of the initial etoposide concentration is recovered, with a 5 % confidence interval. No known etoposide degradation products were found while monitoring changes in the content of the active ingredient. Moreover, the amount of etoposide found in the form of a precipitate corresponded to the missing amount. This allowed us to conclude that precipitation was the only cause of instability in the etoposide solution in these devices. This study allowed us therefore to conclude that etoposide was stable enough, especially at low and medium concentrations, for use in disposable infusion devices such as Intermate® prepared in the Central Chemotherapy Production Facility for day hospital administration in a Paediatrics Unit. It will also allow our clinical team to conduct a future clinical study that will focus on the medico-economic feasibility

of using these infusion devices and on the evaluation of patient and nurse satisfaction. Acknowledgments Mannose-binding protein-associated serine protease The authors are very grateful to Lorna Saint Ange for editing. This stability study was made possible by the provision of the devices by Baxter Oncology. Dr J. Grill has received a grant for the analysis of the clinical use of infusion devices from Baxter Oncology. The authors have no conflicts of interest to declare. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Baxter report 93/REP/NIV/PD/4249/0155. Review of data generated on the stability of ifosfamide, carboplatin, mitomycin and mitoxantrone in infusor and shelf lives allocation. I. Wilmet. 2. Rochard E, Barthes D, Courtois P. Stability and compatibility study of carboplatin with three portable infusion pump reservoirs. Int J Pharm. 1994;101(3):257–62.CrossRef 3. Beijnen JH, Beijnen-Bandhoe AU, Dubbleman AC, et al. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

Comments are closed.